Vivo Capital and Novo Holdings have led a $200 million Series A round for Esco Lifesciences, a Singapore-based manufacturer of biopharma lab equipment and medical devices.
TR Capital and Shenzhen Capital Group have backed the spin-out of six healthcare assets held by China focused GP Huagai Capital into a RMB800 million ($125 million) renminbi-denominated continuation fund.
The Southeast Asian manager will commit up to $100 million to hospital roll-up strategy intended to address rising demand for private healthcare in Malaysia’s underserved territories
In Hummingbird Bioscience and Halodoc, Novo Holdings believes it has backed a potential global leader in hard-to-drug cancer and a likely domestic champion in telemedicine and disease management
Navis Capital Partners has acquired a majority stake in Malaysia-based hospital developer Aurelius Healthcare for an undisclosed sum.
Lilly Asia Ventures has led a $90 million Series B round for Duality Biologics, a Chinese developer of oncology and autoimmune drugs.
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
Legend Capital has spun out the healthcare assets from two of its China venture capital funds into a continuation vehicle supported by Hamilton Lane and Coller Capital. The $270 million deal includes capital for follow-on investments.
Panacea Venture, a China-focused early-stage healthcare investor, has teamed up with Michael Dell’s family office to raise $200 million for a special purpose acquisition company (SPAC).
Hospitals attract most of the capital and interest aimed at Vietnam healthcare. Macro tailwinds are benefiting other parts of the services ecosystem as well, but GPs don’t want to jump too early
KKR has invested $95 million in Indian eyewear retail leader Lenskart via a secondary transaction that facilitated partial exits of undisclosed size for TPG Growth and TR Capital.
DAC Biotech, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised RMB1 billion ($160 million) in Series C funding led by GL Ventures, CDG Capital, and CPE.
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
The contribution CDH Investments has made to China Grand Pharma belies the size of its equity interest in the company. M&A, at home and overseas, has been central to the growth strategy
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
DCP Capital has continued its run of investments in China’s medical devices industry by participating in a Series B funding round for Hangzhou Valgen Medtech.
Wei Fu, the founder and CEO of Asia-focused healthcare investor CBC Group, has launched a special purpose acquisition company (SPAC) to pursue deals in the sector.
China-based medical devices manufacturer Hygea Medical Technology has raised a RMB500 million ($77 million) Series C round led by China Growth Capital.
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has made its first investment in an Asian healthcare company by participating in an $80 million Series C round for Indonesia healthcare technology provider Halodoc.
An investor group including Centurium Capital, CITIC Capital and Hillhouse Capital has completed its protracted pursuit of China Biologic Products Holdings with a $4.6 billion privatization.
Amazon has formed a $250 million fund that will invest in India-based small and medium-sized enterprises (SMEs) with a view to supporting nationwide business digitalization.
Fiture, a Chinese developer of artificial intelligence-enabled home fitness devices, has raised $300 million in Series B funding led by All-Stars Investment, Legend Capital, DST Global, and Coatue Management.